• Glaukos reported topline three-year results from a Phase 3 extension study of Epioxa for keratoconus.
• Follow-up showed sustained disease stabilization with meaningful vision benefits from a single treatment.
• Safety held up over three years with no serious events tied to treatment, supporting a favorable long-term profile.
• Durability data could strengthen the product’s competitive positioning as an epi-on alternative to standard cross-linking procedures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007149511) on October 07, 2026, and is solely responsible for the information contained therein.